Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3CNS 2Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Hepatoblastoma 1Fibrolamellar hepatocellular carcinoma 1

Interventions

X-Rays 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 4Melphalan 4fludarabine 3Granulocyte Colony-Stimulating Factor 3Cyclophosphamide 3Busulfan 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2ensartinib 2Vemurafenib 2Trabectedin 2Thiotepa 2Temozolomide 2Sirolimus 2Mesna 2LY3023414 2Cytoreduction Surgical Procedures 2Cisplatin 2talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Tacrolimus × Gastrointestinal × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡